Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: Prevention of fluid retention

Diabetes

Volumn 56, Issue 1, 2007, Pages 248-255

  Boden, Guenther ^a,b   Homko, Carol ^a   Mozzoli, Maria ^a   Zhang, Meijuan ^a   Kresge, Karen ^a   Cheung, Peter ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; FATTY ACID; FENOFIBRATE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL; TROGLITAZONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; ERYTHROCYTE COUNT; FATIGUE; FATTY ACID BLOOD LEVEL; FEMALE; FLUID RETENTION; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LIVER PAIN; MALE; MONOTHERAPY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PAIN; PRIORITY JOURNAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WATER RETENTION;

ADIPONECTIN; BLOOD GLUCOSE; BODY WATER; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PLACEBOS; PROCETOFEN; SINGLE-BLIND METHOD; THIAZOLIDINEDIONES;

EID: 33847068374     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db06-0481     Document Type: Article

References (33)

1. Bray GA: Medical consequences of obesity. J Clin Endocrinol Metab 89:2583-2589, 2004
2. Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10, 1997
3. Reaven G: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
4. Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L: Insulin resistance and risk of congestive heart failure. JAMA 294:334-341, 2005
5. Boden G, Chen X, Ruiz J, White JV, Rossetti: Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 93:2438-2446, 1994
6. Santomauro ATMG, Boden G, Silva M, Rocha DM, Santos RF, Ursich MJ, Strassmann PG, Wajchenberg BL: Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic nondiabetic subjects. Diabetes 48:1836-1841, 1999
7. Bajaj M, Suraamornkul S, Kashyap S, Cusi K, Mandarino L, DeFronzo RA: Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J Clin Endocrinol Metab 89:4649-4655, 2004
8. Chen X, Iqbal N, Boden G: The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest 103:365-372, 1999
9. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW: Cardiac and glycemic benefits of troglitazone treatment in NIDDM: the Troglitazone Study Group. Diabetes 46:433-439, 1997
10. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hseuh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. Ann Intern Med 128:176-185, 1998
11. Mayerson AB, Hundal RS, Dufour S: The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802, 2002
12. Boden G, Cheung P, Mozzoli M, Fried SK: Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism 52:753-759, 2003
13. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 53:409-435, 2002
14. Wagner JA, Larson PJ, Weiss MS, Miller JL, Doebber TW, Wu MS, Moller DE, Gottesdiener KM: Individual and combined effects of peroxisome proliferator-activated receptor α and γ agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers. J Clin Pharmacol 45:504-513, 2005
15. Lukaski HC: Methods for the assessment of human body composition: traditional and new. Am J Clin Nutr 46:537-556, 1987
16. Owen OE, Trapp VE, Reichard GR Jr, Mozzoli M, Smith R, Boden G: Effects of therapy on the nature and quantity of fuels oxidized during diabetic ketoacidosis. Diabetes 29:365-372, 1980
17. Tappy L, Owen OE, Boden G: Effect of hyperinsulinemia on urea pool size and substrate oxidation rates. Diabetes 37:1212-1216, 1988
18. Rosenblatt JI, Wolfe RR: Calculation of substrate flux using stable isotopes. Am J Physiol 254:E526-E531, 1988
19. Steele R, Wall JS, DeBodo RC, Altszuler N: Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187:15-24, 1956
20. Boden G, Chen X, DeSantis RA, Kendrick Z: Effects of insulin on fatty acid reesterification in healthy subjects. Diabetes 42:1588-1593, 1993
21. Etgen GJ, Oldham BA, Johnson WT, Broderick CL, Montrose CR, Brozinick JT, Misener EA, Bean JS, Bensch WR, Brooks DA, Shuker AJ, Rito CJ, McCarthy JR, Ardecky RJ, Tyhonas JS, Dana SL, Bilakovics JM, Paterniti JR Jr, Ogilvie KM, Liu S, Kauffman RF: A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor α/γ agonist LY465608 ameliorates insulin resistance and diabetic hyperglyecmia while improving cardiovascular risk factors in preclinical models. Diabetes 51:1083-1087, 2002
22. Boden G, Zhang M: Recent findings concerning thiazolidinediones in the treatment of diabetes. Exp Opin Investig Drugs 15:243-250, 2006
23. Itani SI, Ruderman NB, Schmieder F, Boden G: Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and Iκ B-α. Diabetes 51:2005-2011, 2002
24. Boden G, She P, Mozzoli M, Cheung P, Gumireddy K, Reddy P, Xiang X, Luo Z, Ruderman N: Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-κ B pathway in rat liver. Diabetes 54:3458-3465, 2005
25. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE: Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κ B. Nat Med 11:183-190, 2005
26. Hottelart C, El Esper N, Rose F, Achard JM, Fournier A: Fenofibrate increases creatinemia by increasing metabolic production of creatinine. Nephron 92:536-541, 2002
27. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD: Thiazolidinediones expand body fluid volume through PPARγ stimulation of EnaC-mediated renal salt absorption. Nat Med 11:861-866, 2005
28. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert J-M, Winegar DA, Willson TM, Fruchart J-C, Berge RK, Staels B: Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275:16638-16642, 2000
29. Mancini FP, Lanni A, Sabatino L, Moreno M, Giannino A, Contaldo F, Colantuoni V, Goglia F: Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. FEBS Lett 491:154-158, 2001
30. Lee JG, Choi SS, Park MK, An YJ, Seo SY, Kim MC, Hong SH, Hwang TH, Kang DY, Garber AJ, Kim DK: Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochem Biophys Res Commun 296:293-299, 2002
31. Carmona MC, Louche K, Nibbelink M, Prunet B, Bross A, Desbazeille M, Dacquet C, Renard P, Casteilla L, Penicaud L: Fenofibrate prevents rosiglitazone-induced body weight gain in ob/ob mice. Int J Obes 29:864-871, 2005
32. Chaput E, Saladin R, Silvestre M, Edgar AD: Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun 271:445-450, 2000
33. Park CW, Kim HW, Ko SY, Chung HW, Lim SW, Yang CW, Chang YS, Sugawara A, Guan YF, Breyer MD: Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor α. Diabetes 55:885-893, 2006